What is Acromegaly: Causes, Symptoms, & Treatments

Acromegaly is a rare hormonal condition in adults that develops when the body produces too much growth hormone, leading to gradual enlargement of bones and soft tissues over many years and a range of health complications if untreated. With timely acromegaly diagnosis and modern therapies, most people can achieve hormone control, reduce risks, and improve quality of life under specialist endocrine care.​ Understanding your options and asking the right questions can transform outcomes. Let’s read more about it.

What is Acromegaly?

Acromegaly is caused by an increase in IGF-1, a growth hormone, and results in the abnormal growth of bones, skin, cartilage, and internal organs in adults. In most people, a non-cancerous pituitary tumour that releases excess growth hormone is one of the Acromegaly causes. Very rarely, a tumour elsewhere triggers growth hormone–releasing signals, but the pituitary is the usual source.

Why Early Recognition is Crucial?

Acromegaly disease often progresses slowly, so subtle changes in appearance and symptoms are missed for years, yet prolonged exposure to excess GH/IGF‑1 increases risks of heart disease, sleep apnoea, diabetes, colon polyps, and arthritis. Earlier acromegaly diagnosis and treatment lower long-term complications and normalise life expectancy for many, making awareness of signs and screening in high-risk scenarios essential.​

Acromegaly Causes

For accurate diagnosis and clearer understanding, an overview of the causes is the best place to start.

• Acromegaly is caused by a GH-secreting pituitary adenoma in the vast majority of patients, leading to chronically raised IGF‑1 from the liver and other tissues.​
• Rarely, ectopic secretion of growth hormone–releasing hormone (GHRH) from non-pituitary tumours stimulates the pituitary to overproduce GH, but this accounts for a small minority of cases.​

Acromegaly Symptoms

The symptoms below are commonly reported when someone is suffering from this condition.

• Acromegaly symptoms typically develop insidiously and may affect appearance, metabolism, nerves, joints, and vital organs, so clusters of features are a cue to test IGF‑1.​
• Changes in appearance: enlarged hands and feet (ring or shoe size increases), coarser facial features, jaw enlargement, nasal and lip thickening, and skin thickening or oiliness.​
• Oral and ENT: tongue enlargement (macroglossia), wider gaps between teeth, deepened voice, snoring and obstructive sleep apnoea symptoms.​
• Musculoskeletal and nerves: joint pain and stiffness, carpal tunnel syndrome, back pain, and progressive degenerative joint disease that may persist even after hormone control.​
• Metabolic and cardiovascular: fatigue, headaches, high blood pressure, insulin resistance or type 2 diabetes, and cardiomyopathy or rhythm issues in advanced cases.​
• Reproductive and others: menstrual irregularities in women, reduced libido, and excessive sweating.​

Acromegaly Diagnosis

A structured pathway confirms excess GH activity, identifies the cause, and assesses complications to guide acromegaly treatment planning.​

• First-line test: age-adjusted serum IGF‑1; if elevated, acromegaly is very likely and requires confirmation and localisation.​
• Confirmatory testing: an oral glucose tolerance test (OGTT) for GH suppression is used where necessary; however, contemporary consensus notes that a clearly elevated IGF-1 level above a defined threshold in a typical case can confirm the diagnosis.​
• Imaging: pituitary MRI with contrast to detect a microadenoma or macroadenoma and assess optic chiasm proximity and surgical anatomy.​
• Baseline complication screen: glucose/HbA1c, lipids, blood pressure, sleep apnea screening, echocardiogram if cardiac concerns are present, and colon surveillance as clinically indicated.​

Acromegaly Treatment Options

Acromegaly treatment is individualised by tumour size/location, hormone levels, comorbidities, and patient preference, often combining surgery, medicines, and targeted radiation over time with specialist follow-up.​

Pituitary Surgery

Endoscopic transsphenoidal adenomectomy is the standard first-line therapy for most pituitary adenomas, particularly microadenomas and resectable macroadenomas, offering the potential for cure and rapid biochemical improvement. Outcomes vary by tumour invasiveness and surgical expertise, with higher-volume pituitary centres achieving better normalisation rates, supporting referral to experienced teams.​

Medical Therapy

• When surgery is incomplete, not feasible, or declined, or when biochemical control is insufficient, medications are used alone or with radiation to control GH/IGF‑1.​
• Somatostatin analogues (e.g., long-acting formulations) reduce GH secretion and normalise IGF‑1 in many but not all patients, and are frequently used as second-line or adjunctive therapy.​
• Dopamine agonists can be helpful in milder disease or as add-on therapy to improve biochemical control when IGF‑1 remains modestly elevated.​
• GH receptor antagonist therapy (pegvisomant) blocks GH action at its receptor, effectively lowering IGF-1 when other options do not fully control the disease; commissioning and sequencing differ by health system and are often third line.​

Radiation Therapy

Stereotactic radiosurgery or fractionated radiotherapy is considered when residual tumour persists or medical therapy is insufficient, recognising that hormonal control may take years and that pituitary hormone deficits can develop over time. Close endocrine monitoring after radiation is essential to detect and treat hypopituitarism early while tracking IGF‑1 and GH trends.​

Everyday Health: Practical Pointers

• Cardiometabolic health: Monitor blood pressure, glucose/HbA1c, and lipids regularly, and maintain a heart-healthy diet and activity regimen tailored to joint comfort and cardiology advice.​
• Sleep and breathing: Assess and treat obstructive sleep apnea; CPAP and weight management can complement hormone control to improve daytime energy and reduce cardiovascular risk.​
• Musculoskeletal wellbeing: physiotherapy, pain management, joint protection strategies, and, when necessary, orthopaedic input can improve function despite structural joint changes.​
• Eye and pituitary function: monitor for headaches, visual symptoms, and signs of hypopituitarism; routine endocrine panels help guide timely hormone replacement when necessary.​

Health Insurance and Supportive Cover

Comprehensive health insurance in india that supports long-term specialist care, surgery, medications, imaging, sleep studies, and, where necessary, radiotherapy can help ease costs and protect continuity of care over years of follow-up. In India, plans from Niva Bupa are often chosen for wide hospital networks and ongoing support for chronic conditions, with similar access available to NRIs who seek coverage for themselves or family members. When planning and monitoring acromegaly treatment, it’s worth reviewing benefits for endocrine disorders, daycare procedures, and long-term medications to ensure practical, sustained coverage.

Conclusion

Acromegaly disease is a long‑term but manageable condition, usually caused by a benign pituitary tumour that makes too much growth hormone, raising IGF‑1 and gradually affecting many body systems. The main steps in care include prompt diagnosis with IGF-1, a targeted pituitary MRI, and a tailored plan that utilises surgery, medications, and, if necessary, radiotherapy to restore hormones to normal levels. With regular follow‑up, attention to sleep, metabolic, heart, and joint health, and supportive insurance, potentially including options from Niva Bupa, most people can maintain reasonable control and live well with treatment.

FAQs

1. What is the leading cause of acromegaly?

   A GH-secreting pituitary adenoma is the primary cause, leading to elevated IGF-1 and driving tissue overgrowth in adults.​

2. How is acromegaly diagnosed?

   By measuring age-adjusted IGF‑1, using OGTT for GH suppression when needed, and confirming with pituitary MRI to locate the tumour.​

3. Can acromegaly be cured?

   Yes, many are cured with transsphenoidal surgery, especially for small, well-contained tumours, while others achieve control with medicines and/or radiation.​

4. Which medicines are used if surgery is not enough?

   Somatostatin analogues, dopamine agonists, and GH receptor antagonists are used alone or in combination to normalise IGF‑1.​

5. What complications should be monitored long-term?

   Sleep apnoea, diabetes, hypertension, cardiomyopathy, colon polyps, and joint disease require ongoing assessment and treatment after hormonal control.​

6. Does early treatment improve outcomes?

   Earlier normalisation of IGF-1 and GH lowers morbidity and aligns survival closer to that of the general population, underscoring the value of prompt care.​

7. Is health insurance beneficial for managing acromegaly?

   Yes, comprehensive cover for specialist visits, surgery, imaging, medicines, and possible radiotherapy supports continuous, affordable management, including options from Niva Bupa in India.

​